Medtronic plc: Q3 Fiscal 2026 Filing Summary
Business Context and Reporting Period
This summary covers Medtronic plc's Form 10-Q for the quarterly period ended January 23, 2026 (Fiscal Q3 2026) and the nine months ended on that date. Medtronic is a global healthcare technology company operating through four reportable segments: Cardiovascular, Neuroscience, Medical Surgical, and Diabetes. The company is currently executing a strategic plan to separate its Diabetes business into an independent, publicly traded entity named MiniMed Group, Inc., expected to be completed within 18 months of the May 2025 announcement.
Key Financial Metrics
| Metric (in millions) | Q3 2026 | Q3 2025 | 9M 2026 | 9M 2025 |
|---|---|---|---|---|
| Net Sales | $9,017 | $8,292 | $26,557 | $24,610 |
| Operating Profit | $1,464 | $1,646 | $4,594 | $4,519 |
| Net Income (Attributable to Medtronic) | $1,143 | $1,294 | $3,557 | $3,606 |
| Diluted EPS | $0.89 | $1.01 | $2.76 | $2.79 |
| Operating Cash Flow (9M) | $4,757 | $4,516 | $4,757 | $4,516 |
| Free Cash Flow (9M) | $3,341 | $3,116 | $3,341 | $3,116 |
| Total Debt | $28.1B | $28.5B | $28.1B | $28.5B |
| Cash & Investments | $8.4B | $8.9B | $8.4B | $8.9B |
Note: Total Debt includes current debt obligations ($191M) and long-term debt ($27.88B). Cash & Investments includes cash equivalents ($1.15B) and investments ($7.24B).
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 9% year-over-year (YoY) in Q3 and 8% for the nine-month period. Growth was driven by organic volume across most segments and favorable foreign currency impacts.
- Cardiovascular: Sales up 14% (Q3) and 11% (9M), led by Cardiac Rhythm & Heart Failure (+20% Q3) and Structural Heart & Aortic (+6% Q3).
- Diabetes: Sales up 15% (Q3) and 12% (9M), driven by international adoption of the MiniMed 780G system.
- Neuroscience: Sales up 4% (Q3 and 9M).
- Medical Surgical: Sales up 5% (Q3) and 4% (9M).
- Profitability Pressure: Despite revenue growth, Operating Profit declined 11% in Q3 ($1.46B vs $1.65B) due to increased costs.
- Cost of Products Sold: Increased due to approximately $90M in tariff-related duties, $84M in asset write-offs (related to a terminated third-party manufacturing agreement in the Diabetes unit), and unfavorable currency impacts.
- Restructuring: Charges increased to $172M in Q3 (vs $46M prior year), primarily related to the MiniMed separation and other workforce realignments.
- Litigation: Certain litigation charges rose to $62M in Q3 (vs $22M prior year).
- Italian Payback Adjustment: A $39M favorable adjustment to net sales was recorded in the nine months ended Jan 23, 2026, following a legislative decree reducing payback amounts due for years 2015–2018. This contrasts with a $90M negative adjustment in the prior year period.
Guidance, Outlook, and Risks
- MiniMed Separation: The company expects to incur pre-tax restructuring charges of $300M–$500M between Q3 FY2026 and the finalization of the Transition Services Agreement (expected by FY2029). A $500M credit facility has been arranged for the new entity, contingent on the IPO.
- Tariff Impact: Management estimates a pre-tax net tariff impact of $185M for Fiscal 2026, with the majority expected in the second half of the year. This estimate is subject to change based on trade policy developments, including a recent U.S. Supreme Court ruling on tariff policies.
- Acquisitions: On February 3, 2026, Medtronic announced its intent to exercise an option to acquire CathWorks Ltd. for up to $585M, expanding its Coronary & Peripheral Vascular portfolio.
- Legal Contingencies:
- Applied Medical Antitrust Case: A jury awarded Applied Medical $382M in damages (subject to trebling) in an antitrust trial concluded in February 2026. Medtronic has not recorded a liability as the outcome is uncertain pending post-trial motions and appeal.
- Hernia Mesh Litigation: Approximately 10,100 individual plaintiffs are involved in pending lawsuits. No liability has been accrued as the loss is not currently probable or estimable.
- Investment Losses: The company recognized a $90M loss on its Mozarc Medical investment (50% stake in a kidney care joint venture) during the nine months ended Jan 23, 2026.
Investor Verification Checklist
- MiniMed Separation Costs: Verify the timing and magnitude of the remaining $300M–$500M restructuring charges associated with the Diabetes spin-off.
- Tariff Exposure: Monitor the final impact of global trade policies on the estimated $185M FY2026 tariff cost, particularly following the Supreme Court ruling on tariff authority.
- Applied Medical Litigation: Track the status of post-trial motions and potential appeals in the antitrust case, which could result in a significant liability (potentially exceeding $1B if trebled).
- Cardiovascular Growth Sustainability: Assess whether the double-digit growth in Cardiac Rhythm & Heart Failure (driven by Micra and Aurora EV-ICD) is sustainable given competitive pressures.
- Debt Maturity Profile: Review the company's ability to manage debt maturities, noting the recent issuance of €1.5B in senior notes to refinance maturing obligations.